An H1 antihistamine with antimuscarinic and sedative actions. A sedating experience is not equivalent to restorative sleep or preserved performance.
Diphenhydramine acts at histamine H1 receptors and has additional antimuscarinic activity. Different exposures and study populations produce different kinetic and subjective findings. The molecular structure represents the parent base, not the hydrochloride salt used in the cited experiment.
Age differences were observed in one kinetic study but not in another exposure setting; a universal age multiplier is not justified.
Assessment belongs to each claim and outcome. An article’s editorial status is not a grade of a substance’s safety or efficacy.Diphenhydramine inhibits histamine-mediated responses; its additional muscarinic activity makes it pharmacologically broader than an H1-only description. [4]
Experimental inhibition of acetylcholine-driven secretion supports a distinct antimuscarinic mechanism. [4]
Descriptions of experience in their reported context. Direction does not imply benefit, and these observations do not define a universal intensity score.
No significant difference from placebo was detected at this study exposure. This does not negate sedation warnings for the medicine. [3]
What the research measured, for whom, and under which exposure. Findings remain attached to the study’s task or clinical endpoint.
Not assessed. No sourced measured outcomes have been curated for this article.
Published exposure records, distinguished by source category. These describe study or reference context and are not personal dosing recommendations.
25 mg [3]
This particular experiment detected no significant sedation or performance difference versus placebo.
Absorption, metabolism and elimination depend on the analyte, route, formulation, physiology and other exposures.
Young-adult group in a syrup study; the reported variation is not encoded as a range or confidence interval. [2]
The modeled analyte is Diphenhydramine. The curve begins after absorption and distribution; it does not predict onset, felt effects, or an individual’s response.
Route: Oral. Formulation: Syrup. Population: Young-adult group in a study of 21 participants across three age groups.
Group mean after a single 1.25 mg/kg study exposure; not a recommended exposure. Source & context
Study mean: 9.2 hours.
The model uses this single study mean; no range is inferred.
Model: fraction remaining = 2−time / half-life. Assumes a single exposure, instantaneous distribution, and a constant half-life for Diphenhydramine. Formation of metabolites, repeated exposure, and interactions are not modeled. Source & context
9.2 hoursStudy mean [2]
Group mean after a single 1.25 mg/kg study exposure; not a recommended exposure.
13.5 hoursStudy mean [2]
Group mean after a single 1.25 mg/kg study exposure. Other experiments did not reproduce a significant age effect.
A separate lower-exposure crossover experiment did not find significant age differences. Do not use a fixed age-based multiplier. [2]
Related observationAdverse effects, interactions, tolerance and withdrawal in the cited contexts. This section is not an exhaustive interaction checker.
The label warns about drowsiness and additive effects with alcohol and other CNS depressants. [1]
Drying effects and urinary or ocular problems matter in susceptible people; consult the formulation's contraindications and warnings. [1]
Contrasting experiments caution against assigning every older adult the same elimination estimate. [3]
The source, the finding and its limitations. Funding information is reported where curated; an unassessed disclosure does not mean a study had no commercial funding.
Documents antihistamine, anticholinergic and sedative properties and related warnings.
Limitations Formulation-specific labeling; date denotes retrieval, not original approval. It does not establish benefit outside the labeled context.
Funding / disclosures Manufacturer prescribing information hosted by the US National Library of Medicine.
Compared serum elimination and skin-test responses across age groups.
Limitations Small groups and a particular syrup exposure; group means do not predict individual clearance.
Funding / disclosures Not assessed in this draft.
Did not detect significant age effects on kinetics or sedation differences at the tested exposure.
Limitations An undetected difference in one acute experiment does not establish absence of impairment in other settings.
Funding / disclosures NIMH support is listed in the PubMed record; other funding not assessed.
Compared antihistamine and antimuscarinic actions in airway cells.
Limitations Swine cell preparation; cannot determine human clinical benefit or harm magnitude.
Funding / disclosures Not assessed in this draft.
Source of the displayed formula, molecular weight, structure and connectivity SMILES.
Limitations The parent compound identity is distinct from salts, formulations and commercial product quality.
Funding / disclosures US National Library of Medicine.
Each relationship retains its participants, roles and context. Shared membership does not imply that substances should be combined.
Cultured swine airway mucus-gland cells
Limitation Preclinical tissue assay; it does not quantify human cognitive effects.
Evidence strength: not formally assessed.
Syrup study compared younger adults, older adults and children
Limitation A separate lower-exposure study found no significant age effect.
Evidence strength: not formally assessed.
Not assessed. Absence of a legal record is not a statement of legal status.
This article is a sourced draft. Editorial review has not been recorded. Content date: Sep 29, 2026.